Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells

Diseases of the Esophagus

Volumn 23, Issue 2, 2010, Pages 83-93

  Goldman, A ^a,b   Condon, A ^a   Adler, E ^a   Minnella, M ^a   Bernstein, C ^a   Bernstein, H ^a,b   Dvorak, K ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Barrett's esophagus; Bileacids; Ursodeoxycholic acid

Indexed keywords

5 CHLOROMETHYLFLUORESCEIN DIACETATE; BILE ACID; FLUORESCEIN DIACETATE; FLUORESCENT DYE; GLYCOURSODEOXYCHOLIC ACID; HYDROETHIDINE; MANGANESE SUPEROXIDE DISMUTASE; PEROXIREDOXIN 3; REACTIVE OXYGEN METABOLITE; TRYPAN BLUE; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; 8-OXO-7-HYDRODEOXYGUANOSINE; ANTIOXIDANT; DEOXYCHOLIC ACID; DEOXYGUANOSINE; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; PROTECTIVE AGENT; RNA; SCAVENGER; SUPEROXIDE DISMUTASE; TAUROCHOLIC ACID; THIOL DERIVATIVE;

ARTICLE; BARRETT ESOPHAGUS; CANCER PREVENTION; CELL PROLIFERATION; CELL PROTECTION; CELL VIABILITY; COMET ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DNA DAMAGE; IMMUNOHISTOCHEMISTRY; OXIDATIVE STRESS; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ACID; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL LINE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECTS; ESOPHAGUS; HUMAN; PATHOLOGY; TIME;

ANTIOXIDANTS; BARRETT ESOPHAGUS; BILE ACIDS AND SALTS; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; CYTOPROTECTION; DEOXYCHOLIC ACID; DEOXYGUANOSINE; DNA DAMAGE; ESOPHAGUS; FREE RADICAL SCAVENGERS; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; GLYCODEOXYCHOLIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; OXIDATIVE STRESS; PROTECTIVE AGENTS; REACTIVE OXYGEN SPECIES; RNA; SULFHYDRYL COMPOUNDS; SUPEROXIDE DISMUTASE; TAUROCHOLIC ACID; TIME FACTORS; URSODEOXYCHOLIC ACID;

EID: 77953151908     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.00993.x     Document Type: Article

References (58)

1. Demeester T R. Management of adenocarcinoma arising in Barrett's esophagus. Semin Thorac Cardiovasc Surg 1997; 9 (3): 290-301.
2. Drewitz D J, Sampliner R E, Garewal H S. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92 (2): 212-5.
3. Falk G W. Barrett's esophagus. Gastroenterology 2002; 122 (6): 1569-91.
4. Gillen P, Keeling P, Byrne P J, Healy M, O'Moore R R, Hennessy T P. Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg 1988; 75 (6): 540-3.
5. Iftikhar S Y, Ledingham S, Steele R J et al. Bile reflux in columnar-lined Barrett's oesophagus. Ann R Coll Surg Engl 1993; 75 (6): 411-6.
6. Nehra D, Howell P, Williams C P, Pye J K, Beynon J. Toxic bileacids in gastro-oesophageal reflux disease: influence of gastric acidity. Gut 1999; 44 (5): 598-602.
7. Stein H J, Kauer W K, Feussner H, Siewert J R. Bileacids as components of the duodenogastric refluxate: detection, relationship to bilirubin, mechanism of injury, and clinical relevance. Hepatogastroenterology 1999; 46 (25): 66-73.
8. Wetscher G J, Perdikis G, Kretchmar D H et al. Esophagitis in Sprague-Dawley rats is mediated by free radicals. Dig Dis Sci 1995; 40 (6): 1297-305.
9. Sihvo E I, Ruohtula T, Auvinen M I, Koivistoinen A, Harjula A L, Salo J A. Simultaneous progression of oxidative stress and angiogenesis in malignant transformation of Barrett esophagus. J Thorac Cardiovasc Surg 2003; 126 (6): 1952-7.
10. Terry P, Lagergren J, Ye W, Nyren O, Wolk A. Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 2000; 87 (5): 750-4.
11. Fountoulakis A, Martin I G, White K L et al. Plasma and esophageal mucosal levels of vitamin C: role in the pathogenesis and neoplastic progression of Barrett's esophagus. Dig Dis Sci 2004; 49 (6): 914-9.
12. Clemons N J, McColl K E, Fitzgerald R C. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 2007; 133 (4): 1198-209.
13. Dvorak K, Fass R, Dekel R et al. Esophageal acid exposure at pH < or = 2 is more common in Barrett's esophagus patients and is associated with oxidative stress. Dis Esophagus 2006; 19 (5): 366-72.
14. Jenkins G J, D'Souza F R, Suzen S H et al. Deoxycholic acid at neutral and acid pH, is genotoxic to oesophageal cells through the induction of ROS: the potential role of anti-oxidants in Barrett's oesophagus. Carcinogenesis 2007; 28 (1): 136-42.
15. Dvorak K, Payne C M, Chavarria M et al. Bileacids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 2007; 56 (6): 763-71.
16. Bernstein C, Bernstein H, Payne C M, Beard S E, Schneider J. Bile salt activation of stress response promoters in Escherichia coli. Curr Microbiol 1999; 39 (2): 68-72.
17. Bernstein H, Payne C M, Bernstein C, Schneider J, Beard S E, Crowley C L. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol Lett 1999; 108 (1): 37-46.
18. Payne C M, Crowley C, Washo-Stultz D et al. The stressresponse proteins poly(ADP-ribose) polymerase and NF-kappaB protect against bile salt-induced apoptosis. Cell Death Differ 1998; 5 (7): 623-36.
19. Nilsell K, Angelin B, Leijd B, Einarsson K. Comparative effects of ursodeoxycholic acid and chenodeoxycholic acid on bile acid kinetics and biliary lipid secretion in humans. Evidence for different modes of action on bile acid synthesis. Gastroenterology 1983; 85 (6): 1248-56.
20. Alberts D S, Martinez M E, Hess L M et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97 (11): 846-53.
21. Earnest D L, Holubec H, Wali R K et al. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid. Cancer Res 1994; 54 (19): 5071-4.
22. Wali R K, Frawley B P, Jr., Hartmann S et al. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: potential roles of protein kinase C-alpha, -beta II, and -zeta. Cancer Res 1995; 55 (22): 5257-64.
23. Jacoby R F, Cole C E, Hawk E T, Lubet R A. Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004; 127 (3): 838-44.
24. Wali R K, Khare S, Tretiakova M et al. Ursodeoxycholic acid and F(6)-D(3) inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cadherin. Cancer Epidemiol Biomarkers Prev 2002; 11 (12): 1653-62.
25. Loddenkemper C, Keller S, Hanski M L et al. Prevention of colitis-associated carcinogenesis in a mouse model by diet supplementation with ursodeoxycholic acid. Int J Cancer 2006; 118 (11): 2750-7.
26. Bernstein C, Payne C M, Bernstein H, Garewal H. Activation of the metallothionein IIA promoter and other key stress response elements by ursodeoxycholate in HepG2 cells: relevance to the cytoprotective function of ursodeoxycholate. Pharmacology 2002; 65 (1): 2-9.
27. Im E, Martinez J D. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J Nutr 2004; 134 (2): 483-6.
28. Mazzella G, Parini P, Bazzoli F et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis. Dig Dis Sci 1993; 38 (5): 896-902.
29. Lapenna D, Ciofani G, Festi D et al. Antioxidant properties of ursodeoxycholic acid. Biochem Pharmacol 2002; 64 (11): 1661-7.
30. Ljubuncic P, Abu-Salach O, Bomzon A. Ursodeoxycholic acid and superoxide anion. World J Gastroenterol 2005; 11 (31): 4875-8.
31. Ljubuncic P, Tanne Z, Bomzon A. Ursodeoxycholic acid suppresses extent of lipid peroxidation in diseased liver in experimental cholestatic liver disease. Dig Dis Sci 2000; 45 (10): 1921-8.
32. Serviddio G, Pereda J, Pallardo F V et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39 (3): 711-20.
33. Marteau P, Chazouilleres O, Myara A, Jian R, Rambaud J C, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bileacids in man. Hepatology 1990; 12 (5): 1206-8.
34. Rudolph G, Kloeters-Plachky P, Sauer P, Stiehl A. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate. Eur J Clin Invest 2002; 32 (8): 575-80.
35. Rost D, Rudolph G, Kloeters-Plachky P, Stiehl A. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis. Hepatology 2004; 40 (3): 693-8.
36. Bozikas A, Marsman W A, Rosmolen W D et al. The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. Dis Esophagus 2008; 21 (4): 346-54.
37. Roda E, Mazzella G, Bazzoli F et al. Effect of ursodeoxycholic acid administration on biliary lipid secretion in primary biliary cirrhosis. Dig Dis Sci 1989; 34 (Suppl 12): 52S-8.
38. KauerWK, Peters J H, DeMeester T R et al. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997; 122 (5): 874-81.
39. Theisen J, Nehra D, Citron D et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bileacids. J Gastrointest Surg 2000; 4 (1): 50-4.
40. Dvorakova K, Waltmire C N, Payne C M, Tome M E, Briehl M M, Dorr R T. Induction of mitochondrial changes in myeloma cells by imexon. Blood 2001; 97 (11): 3544-51.
41. Anderson L A, Murray L J, Murphy S J et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003; 52 (8): 1081-4.
42. Beales I L, Ogunwobi O O. Leptin synergistically enhances the anti-apoptotic and growth-promoting effects of acid in OE33 oesophageal adenocarcinoma cells in culture. Mol Cell Endocrinol 2007; 274 (1-2): 60-8.
43. Fitzgerald R C, Omary M B, Triadafilopoulos G. Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 1996; 98 (9): 2120-8.
44. Feagins L A, Zhang H Y, Hormi-Carver K et al. Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 2007; 102 (1): 10-20.
45. Jaiswal K, Lopez-Guzman C, Souza R F, Spechler S J, Sarosi G A, Jr. Bile salt exposure increases proliferation through p38 and ERK MAPK pathways in a non-neoplastic Barrett's cell line. Am J Physiol Gastrointest Liver Physiol 2006; 290 (2): G335-42.
46. Jiang Z R, Gong J, Zhang Z N, Qiao Z. Influence of acid and bile acid on ERK activity, PPARgamma expression and cell proliferation in normal human esophageal epithelial cells. World J Gastroenterol 2006; 12 (15): 2445-9.
47. Zurgil N, Kaufman M, Solodiev I, Deutsch M. Determination of cellular thiol levels in individual viable lymphocytes by means of fluorescence intensity and polarization. J Immunol Methods 1999; 229 (1-2): 23-34.
48. Jolly A J,Wild C P,Hardie L J. Acid and bile salts induce DNA damage in human oesophageal cell lines. Mutagenesis 2004; 19 (4): 319-24.
49. Jean-Louis S, Akare S, Ali M A, Mash E A, Jr., Meuillet E, Martinez J D. Deoxycholic acid induces intracellular signaling through membrane perturbations. J Biol Chem 2006; 281 (21): 14948-60.
50. Dvorak K, Chavarria M, Payne C M et al. Activation of the interleukin-6/STAT3 antiapoptotic pathway in esophageal cells by bileacids and low pH: relevance to Barrett's esophagus. Clin Cancer Res 2007; 13 (18 Pt 1): 5305-13.
51. Tan K P, Yang M, Ito S. Activation of nuclear factor (erythroid-2 like) factor 2 by toxic bileacids provokes adaptive defense responses to enhance cell survival at the emergence of oxidative stress. Mol Pharmacol 2007; 72 (5): 1380-90.
52. Guldutuna S, ZimmerG, Imhof M, Bhatti S, You T, Leuschner U. Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]. Gastroenterology 1993; 104 (6): 1736- 44.
53. Stiehl A, Rudolph G, Raedsch R et al. Ursodeoxycholic acidinduced changes of plasma and urinary bileacids in patients with primary biliary cirrhosis. Hepatology 1990; 12 (3 Pt 1): 492-7.
54. Brito M A, Lima S, Fernandes A et al. Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. Neurotoxicology 2008; 29 (2): 259-69.
55. Rodrigues C M, Fan G, Wong P Y, Kren B T, Steer C J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998; 4 (3): 165-78.
56. Okada K, Shoda J, Taguchi K et al. Ursodeoxycholic acid stimulates Nrf2-mediated hepatocellular transport, detoxification, and antioxidative stress systems in mice. Am J Physiol Gastrointest Liver Physiol 2008; 295 (4): G735-47.
57. Freese E, Cashel M. Crosslinking of deoxyribonucleic acid by exposure to low pH. Biochim Biophys Acta 1964; 91: 67-77.
58. Yuan J, Narayanan L, Rockwell S, Glazer P M. Diminished DNA repair and elevated mutagenesis in mammalian cells exposed to hypoxia and low pH. Cancer Res 2000; 60 (16): 4372